Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice

Journal of Hypertension

Volumn 29, Issue 2, 2011, Pages 299-308

  George, Joseph ^a   D'Armiento, Jeanine ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

matrix metalloproteinases; MMP 9 transgene; monocrotaline; pulmonary arterial hypertension; pulmonary occlusion; right ventricular pressure

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIGEN; BETA ACTIN; GELATINASE B; MAC 3 ANTIGEN; MONOCROTALINE; UNCLASSIFIED DRUG;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INTIMA; LUNG CAPILLARY; MACROPHAGE; MONONUCLEAR CELL; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE; ZYMOGRAPHY;

EID: 78651337549     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328340a0e4     Document Type: Article

References (37)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719-725.
2. Raiesdana A, Loscalzo J. Pulmonary arterial hypertension. Ann Med 2006; 38:95-110.
3. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43:25S-32S.
4. Theo Schermuly R, Ardeschir Ghofrani H, Weissmann N. Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. Curr Top Dev Biol 2005; 67:251-284. (Pubitemid 43588855)
5. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007; 28:23-42.
6. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118:2372-2379.
7. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-1665.
8. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S-24S. (Pubitemid 38759713)
9. Kay JM, Heath D. Crotalaria spectabilis: the pulmonary hypertension plant. Springfield, IL: Thomas; 1969. pp. 1-146.
10. Wilson DW, Segall HJ, Pan LC, Lamé MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22:307-325.
11. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988; 255:H1484-H1491.
12. Molteni A, Ward WF, Ts'ao CH, Solliday NH. Monocrotaline pneumotoxicity in mice. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 57:149-155.
13. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002; 3:409-421.
14. Lagente V, Manoury B, Nénan S, Le Quément C, Martin-Chouly C, Boichot E. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz J Med Biol Res 2005; 38:1521-1530.
15. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, D'Armiento J. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1149-L1157.
16. Thakker-Varia S, Tozzi CA, Poiani GJ, Babiarz JP, Tatem L, Wilson FJ, Riley DJ. Expression of matrix-degrading enzymes in pulmonary vascular remodeling in the rat. Am J Physiol 1998; 275:L398-L406.
17. Novotná J, Herget J. Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 2002; 51:323-334.
18. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001; 18:838-845.
19. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005; 38:73-83.
20. Kolettis T, Vlahos AP, Louka M, Hatzistergos KE, Baltogiannis GG, Agelaki MM, et al. Characterisation of a rat model of pulmonary arterial hypertension. Hell J Cardiol 2007; 48:206-210.
21. Ito T, Okada T, Miyashita H, Nomoto T, Nonaka-Sarukawa M, Uchibori R, et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res 2007; 101:734-741.
22. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In: Rubin L, Rich S, editors. Primary pulmonary hypertension. New York, NY: Marcel Dekker; 1997. pp. 83-129.
23. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotalineinduced fatal pulmonary hypertension in rats. Circ Res 2004; 94:385-393.
24. Kamezaki F, Tasaki H, Yamashita K, Tsutsui M, Koide S, Nakata S, et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2008; 177:219-226.
25. Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol 2008; 295:H677-H690.
26. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005; 25:834-842.
27. Cantini-Salignac C, Lartaud I, Schrijen F, Atkinson J, Chabot F. Metalloproteinase-9 in circulating monocytes in pulmonary hypertension. Fundam Clin Pharmacol 2006; 20:405-410.
28. Umar S, Hessel M, Steendijk P, Bax W, Schutte C, Schalij M, et al. Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract 2007; 203:863-872.
29. Lema?̂tre V, Kim HE, Forney-Prescott M, Okada Y, D'Armiento J. Transgenic expression of matrix metalloproteinase-9 modulates collagen deposition in a mouse model of atherosclerosis. Atherosclerosis 2009; 205:107-112.
30. Iwasaki T, Takahashi T, Shimizu H, Ohmori E, Morimoto T, Kajiya M, et al. Increased pulmonary heme oxygenase-1 and delta-aminolevulinate synthase expression in monocrotaline-induced pulmonary hypertension. Curr Neurovasc Res 2005; 2:133-139.
31. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293:L583-L590.
32. Lee KM, Tsai KY, Wang N, Ingber DE. Extracellular matrix and pulmonary hypertension: control of vascular smooth muscle cell contractility. Am J Physiol 1998; 274:H76-H82.
33. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45:173-202.
34. Rabinovitch M. Pathobiology of pulmonary hypertension. Ann Rev Pathol Mech Dis 2002; 2:369-399.
35. Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997; 150:1349-1360.
36. Merklinger S. The pathobiology of pulmonary hypertension: lessons from experimental studies. In: Redington AN, Van Arsdell GS, Anderson RH, editors. Congenital diseases in the right heart. London: Springer; 2009. pp. 39-47.
37. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-b1 and bone morphogenetic proteins. Circulation 2001; 104:790-795.